CollPlant Biotechnologies (CLGN) Projected to Announce Quarterly Earnings on Thursday

CollPlant Biotechnologies (NASDAQ:CLGN) is expected to post its Q2 2026 results before the market opens on Thursday, August 20th. Analysts expect the company to announce earnings of ($0.2448) per share and revenue of $0.48 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 26, 2026 at 12:30 PM ET.

CollPlant Biotechnologies (NASDAQ:CLGN) last issued its quarterly earnings data on Saturday, May 30th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. The business had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.46 million. CollPlant Biotechnologies had a negative net margin of 683.68% and a negative return on equity of 218.81%.

CollPlant Biotechnologies Trading Down 3.0%

Shares of NASDAQ CLGN opened at $0.32 on Tuesday. The firm’s 50-day moving average price is $0.34 and its 200-day moving average price is $0.50. The stock has a market capitalization of $4.62 million, a price-to-earnings ratio of -0.22 and a beta of 1.67. CollPlant Biotechnologies has a 12-month low of $0.27 and a 12-month high of $3.18.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded CollPlant Biotechnologies from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, June 8th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $11.50.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.